Objective
Short Bowel Syndrome (SBS) is a condition that occurs when part or the entire small intestine is missing or has been removed during surgery. This condition renders the bowel incapable of fulfilling its nutritional function (intestinal failure). There is no cure for SBS. Parenteral (intravenous) nutrition (PN) and bowel transplantation are currently the preferred options for nutrition in children and adults who have lost their bowel. PN offers a low survival rate, compromised quality of life, and the economic cost for each patient is estimated to be 55,000 euro/year. Small intestinal transplant is also an option with one-year and 4-year survival rates of 90% and 60% respectively. However, because of the shortage of organs, high mortality, the severe side effects of immunosuppression and low quality of life, this is still a sub-optimal solution. The objective of this programme is to deliver a functional bowel reconstruction option to patients with SBS through an autologous tissue engineering strategy, overcoming the shortage of organs, and avoiding the need for immunosuppression. It will be achieved by identifying the best autologous cell source; providing the ideal scaffold; engineering functional intestinal mucosa for transplantation and engaging with patients, scientists and public. The work is designed to lead directly to a clinical trial for the application of the optimal protocol for tissue-engineered intestinal mucosa. The consortium is uniquely positioned to complete this ambitious effort as we have an internationally pre-eminent, multi-disciplinary team, which possesses a combination of expertise from basic molecular biology, engineering, and surgery, combining knowledge from universities, hospitals and industry. Importantly we are one of the few groups in the world with experience, infrastructure, and track record to translate regenerative medicine solutions to patients, including true clinical translation of tissue engineered organs.
Fields of science
- medical and health sciencesclinical medicinesurgery
- medical and health sciencesmedical biotechnologytissue engineering
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health scienceshealth sciencesnutrition
- medical and health sciencesclinical medicinetransplantation
Programme(s)
Funding Scheme
RIA - Research and Innovation action
Coordinator
WC1E 6BT London
United Kingdom
See on map
Participants (8)
1011 JV Amsterdam
See on map
1165 Kobenhavn
See on map
NW1 1AT London
See on map
CB25 9TL Cambridge
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1015 Lausanne
See on map
CB2 1TN Cambridge
See on map
90027 6062 Los Angeles,ca
See on map
EH8 9YL Edinburgh
See on map